PEGBIO CO-B (ASX: 02565) has announced that its core product, Vipenatide Injection (brand name: Paidakang®), has been included in the preliminary formal review list for the 2026 National Reimbursement Drug List adjustment, as published by the National Healthcare Security Administration.

The product is listed as item 242 under the "Western and Chinese Patent Medicines Outside the Current List - Basic List," categorized as a western medicine. It passed the review under "Condition 1 for drugs outside the current list" and is marked as an exclusive product.

Vipenatide Injection is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) independently developed by the company for blood glucose control in adult patients with type 2 diabetes.

The product received marketing approval from the National Medical Products Administration in 2025. It represents the group's first innovative drug to gain market approval and is a core asset in its transition from R&D innovation to commercial realization.

The board believes that passing this initial review for the 2026 National Reimbursement Drug List adjustment signifies the product's entry into the subsequent evaluation process for national reimbursement list inclusion. This is a critical milestone in its post-approval market access journey.

If the product is successfully included in the national reimbursement list in subsequent stages, it is expected to significantly enhance its payment accessibility, patient affordability, and clinical adoption. This would further unlock its commercial potential in the type 2 diabetes treatment market and positively drive the group's revenue growth, cash flow improvement, and the revaluation of its core product.

As the group's first commercialized innovative drug, the progress in Vipenatide Injection's reimbursement access is a vital step in advancing the full-chain value conversion from "R&D innovation - product approval - commercialization - reimbursement access - market expansion."

The group will use this successful initial review as an opportunity to actively advance subsequent expert evaluations, negotiations, and related application work. Efforts will focus on clinical value, patient benefit, pharmacoeconomic value, and payment system compatibility. The goal is to strive for Vipenatide Injection to benefit a broader population of diabetes patients and continuously enhance the market competitiveness and long-term commercial value of the group's core products.